TM
CLPT icon

Torren Management’s ClearPoint Neuro CLPT Stock Holding History

Torren Management’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$642 Hold
36
– – ﹤0.01% 827
2026
Q1 		$328 Hold
36
– – ﹤0.01% 920
2025
Q4 		$492 Buy
+36
New +$667 ﹤0.01% 1336

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CCM
Conway Capital Management Burbank, California $225M AUM 19.09% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Torren Management's CLPT Position: Q2 2026 in Review

Torren Management held its ClearPoint Neuro (CLPT) position steady in Q2 2026 at 36 shares worth $642. The position accounts for ﹤0.01% of the portfolio, ranked #827.

Torren Management first reported a position in CLPT in Q4 2025 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • Torren Management held 36 shares of ClearPoint Neuro worth $642 as of Q2 2026.
  • Torren Management left its ClearPoint Neuro share count unchanged in Q2 2026.
  • ClearPoint Neuro made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #827 holding.
  • Torren Management first reported a position in ClearPoint Neuro in Q4 2025 and has held it in 3 quarters since.
  • 45 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.